25,99 €
inkl. MwSt.
Erscheint vorauss. 27. November 2025
13 °P sammeln
Andere Kunden interessierten sich auch für
![Exploring Sleep Disturbance in Central Nervous System Disorders]( "Exploring Sleep Disturbance in Central Nervous System Disorders")
Exploring Sleep Disturbance in Central Nervous System Disorders22,99 €![Multimodal Biomarkers for Central Nervous System Disorders]( "Multimodal Biomarkers for Central Nervous System Disorders")
Multimodal Biomarkers for Central Nervous System Disorders18,99 €![Examining the State of the Science of Mammalian Embryo Model Systems]( "Examining the State of the Science of Mammalian Embryo Model Systems")
Examining the State of the Science of Mammalian Embryo Model Systems58,99 €![Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments]( "Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments")
Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments44,99 €![The Organization of the Central Nervous System]( "The Organization of the Central Nervous System")
The Organization of the Central Nervous System20,99 €![Characterization of Kinin Action and Kinin Receptors in Central Nervous System Tissue]( "Characterization of Kinin Action and Kinin Receptors in Central Nervous System Tissue")
Characterization of Kinin Action and Kinin Receptors in Central Nervous System Tissue68,99 €![The Central Nervous System and Behavior; Transactions; 1960]( "The Central Nervous System and Behavior; Transactions; 1960")
The Central Nervous System and Behavior; Transactions; 196026,99 €
Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have recently received a lot of national attention. Repurposing GLP-1R agonists to treat some central nervous disorders is promising, but comparatively understudied. At a September 2024 workshop, the National Academies Forum on Neuroscience and Nervous System Disorders reviewed the current knowledge and research gaps about the mechanisms of action of GLP-1R agonists in the brain, and the evidence of their clinical efficacy for eating disorders, neurodegenerative diseases, substance use disorders, and pain.